Valeo Pharma Inc.
VPHIF
$0.0469
-$0.0471-50.11%
| 07/31/2024 | 04/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -11.62% | 3.83% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.62% | 3.83% | |||
| Cost of Revenue | -19.17% | -0.87% | |||
| Gross Profit | 17.75% | 27.34% | |||
| SG&A Expenses | -32.00% | -5.24% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.00% | -2.56% | |||
| Operating Income | 68.94% | 20.37% | |||
| Income Before Tax | -3.93% | -13.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3.93% | -13.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.93% | -13.09% | |||
| EBIT | 68.94% | 20.37% | |||
| EBITDA | 81.29% | 24.10% | |||
| EPS Basic | -3.95% | 1.35% | |||
| Normalized Basic EPS | 38.90% | -8.67% | |||
| EPS Diluted | -3.95% | 1.35% | |||
| Normalized Diluted EPS | 38.90% | -8.67% | |||
| Average Basic Shares Outstanding | 0.00% | 14.56% | |||
| Average Diluted Shares Outstanding | 0.00% | 14.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
